Video

Adverse Events Tied to Treatment for Myeloproliferative Neoplasms

Author(s):

Ruben Mesa, M.D.,Rami S. Komrokji, M.D.

Expert perspectives on the possible adverse events patients may encounter while receiving treatment for myeloproliferative neoplasms.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of a man with text.
Ojjaara helps patients with myelofibrosis by reducing spleen size, easing symptoms, and improving anemia to boost independence from blood transfusions.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
Related Content
Long-term follow-up data from the phase 3 MANIFEST 2 clinical trial have been revealed: © stock.adobe.com
August 15th 2025

Pelabresib Plus Rituxan Elicits Meaningful Responses in Myelofibrosis

Alex Biese
Cancer Horizons podcast logo
August 15th 2025

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
Cytopenia at myelofibrosis diagnosis raises risk of acute myeloid leukemia and lowers survival: © stock.adobe.com.
August 15th 2025

Cytopenia in Myelofibrosis Linked to Higher AML Risk, Lower Survival

Spencer Feldman
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
August 15th 2025

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
The FDA granted fast track designation to nuvisertib for those with intermediate or high-risk myelofibrosis: © stock.adobe.com.
August 15th 2025

FDA Grants Fast Track Designation to Nuvisertib in Myelofibrosis

Spencer Feldman
Image of blood cells.
August 15th 2025

Rusfertide Reduces Phlebotomy Need, Improves Quality of Life in Polycythemia Vera

Ryan Scott